S. Goldberg

M. Prilutskaya, H. Lazarus, A. Pecora, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

H. Kantarjian, J. Cortes, J. Kolitz, 2015, Cancer.

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

R. Paquette, H. Khoury, M. Mauro, 2013 .

The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.

D. Siegel, D. Vesole, A. Goy, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

J. Radich, M. Heinrich, J. Cortes, 2019, Leukemia & lymphoma.

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

S. Goldberg, E. Wu, Lei Chen, 2013, Current medical research and opinion.

Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

J. Parrillo, S. Goldberg, I. Sawczuk, 2020, medRxiv.

Treatment of extensive chronic graft‐versus‐host disease with extracorporeal photochemotherapy

S. Goldberg, E. Bisaccia, M. Palangio, 2006, Journal of clinical apheresis.

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

P. Hari, D. Madduri, J. Castillo, 2020, Leukemia & lymphoma.

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

J. Burke, J. Radich, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database

E. Chen, S. Goldberg, N. Mody-Patel, 2008 .

COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey

K. Hoffman, S. Goldberg, J. Hervey, 2021, JMIR public health and surveillance.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

M. Deininger, R. Stone, H. Khoury, 2016, Clinical lymphoma, myeloma & leukemia.

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

A. Calise, R. Sweeney, Yizhao Zhou, 2020, BMC Infectious Diseases.

CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY

R. Paquette, M. Mauro, S. Goldberg, 2015 .

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

P. Westervelt, P. Fenaux, H. Fingert, 2014, Leukemia research reports.

Mobilization of peripheral blood stem cells by subcutaneous injections of yeast‐derived granulocyte macrophage colony stimulating factor: A phase I‐II study

S. Goldberg, T. Klumpp, John Macdonald, 1993, Stem cells.

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.

A. Pecora, S. Waintraub, S. Goldberg, 2002, Blood.

Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.

D. Siegel, D. Vesole, S. Goldberg, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

P. Greenberg, A. Verma, S. Parmar, 2013, Leukemia.

Treatment of Peripheral T‐Cell Lymphoma in Community Settings

A. Goy, S. Goldberg, T. Feldman, 2017, Clinical lymphoma, myeloma & leukemia.

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

R. Larson, G. Martinelli, J. Cortes, 2016 .

P001 Incidence of myelodysplastic syndromes in the United States medicare population

S. Goldberg, N. Mody-Patel, N. Warnock, 2007 .

The 5q- syndrome: a single-institution study of 43 consecutive patients.

A. Tefferi, G. Dewald, John Q. Su, 1993, Blood.

P117 Prevalence of cardiac disease among a US medicare population with myelodysplastic syndromes

S. Goldberg, N. Mody-Patel, N. Warnock, 2007 .

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.

R. Madan, A. Pecora, S. Goldberg, 2003, Blood.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

H. Kantarjian, G. Martinelli, J. Cortes, 2018, Blood.

Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients.

S. Goldberg, K. Mangan, T. Klumpp, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2012, The Lancet. Oncology.

Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial.

D. Steensma, S. Goldberg, 2009 .

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

J. Issa, P. Marks, I. Gojo, 2009 .

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

J. Issa, P. Marks, A. Yang, 2014, British journal of haematology.

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

R. Larson, M. Baccarani, C. Sawyers, 2005 .

Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities.

S. Goldberg, 2015, Clinical lymphoma, myeloma & leukemia.

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

J. Vose, K. Savage, D. Neuberg, 2005 .

A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

P. Stiff, A. Pecora, S. Goldberg, 2001, Bone Marrow Transplantation.

Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.

E. Pearlman, S. Goldberg, E. Pearlman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

J. Radich, J. Cortes, M. Albitar, 2014, Archives of pathology & laboratory medicine.

Feasibility of Peripheral Blood Sampling and Correlation Between Early and Late Responses in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: Post-Hoc Analyses of Molecular Monitoring of Imatinib Response in the RIGHT Study

J. Radich, J. Cortes, M. Albitar, 2012 .

High-dose (HD) imatinib in patients (pts) with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial

H. Kantarjian, J. Cortes, F. Giles, 2005 .

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

G. Martinelli, M. Tallman, M. Levis, 2013 .

Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.

J. Winter, S. Karandish, H. Lazarus, 2001, Cytotherapy.

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

G. Garcia-Manero, P. Fenaux, K. Ozawa, 2016 .

Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety

R. Stone, H. Khoury, M. Mauro, 2008 .

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2010, British journal of haematology.

Vincristine Sulfate Liposomes Injection (Marqibo®) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

G. Schiller, S. Goldberg, L. Damon, 2011 .

A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

L. Silverman, S. Parmar, H. Kantarjian, 2008 .

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

J. Issa, P. Marks, I. Gojo, 2008 .

Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

R. Larson, G. Martinelli, J. Cortes, 2017, The Lancet. Oncology.

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study

D. Berry, J. Landolfi, S. Berry, 2020, medRxiv.

A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs.

A. Norden, A. Goy, A. Pecora, 2018, The oncologist.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in

Martin C. Müller, M. Baccarani, H. Kantarjian, 2013 .

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

M. Baccarani, H. Kantarjian, B. Druker, 2007, Blood.

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

R. Pe Benito, S. Skrzypczak, A. Pecora, 2017, Clinical lung cancer.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

J. Vose, A. LaCasce, S. de Vos, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

D. Siegel, Jaeil Ahn, A. Goy, 2020, The Lancet Rheumatology.

Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer

A. Norden, S. Goldberg, M. Gutierrez, 2019, JCO precision oncology.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Scott E. Smith, A. Nagler, H. Kantarjian, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COVID-19 vaccine hesitancy among individuals with cancer, autoimmune diseases, and other serious comorbid conditions

S. Goldberg, J. Hervey, B. Loew, 2021, medRxiv.

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Susan Branford, Ricardo Pasquini, Fabrizio Pane, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

R. Collins, P. Hari, M. Maris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying and treating imatinib failure in chronic myelogenous leukemia: a practical review of treatment guidelines and available agents

S. Goldberg, Aisha Masood, 2009 .

Considerations for Successful Treatment‐free Remission in Chronic Myeloid Leukemia

M. Mauro, S. Goldberg, M. Savona, 2017, Clinical lymphoma, myeloma & leukemia.

Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation.

J. Herman, E. Pearlman, S. Goldberg, 1996, Bone marrow transplantation.

Association between antibodies reactive with neutrophils, rate of neutrophil engraftment, and incidence of post-engraftment neutropenia following BMT.

J. Herman, S. Goldberg, K. Mangan, 1996, Bone marrow transplantation.

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

D. Siegel, D. Vesole, A. Goy, 2019, Blood.

Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses.

S. Goldberg, K. Mangan, F. Au, 1995, Journal of hematotherapy.

Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion

S. Goldberg, A. Tefferi, M. Dhodapkar, 1994, American journal of hematology.

Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.

R. Korngold, A. Pecora, S. Goldberg, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A. Pecora, S. Goldberg, R. Preti, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

S. Goldberg, S. Faderl, C. Howlett, 2015 .

Patients with Chronic Myelogenous Leukemia May Not Want to Discontinue Tyrosine Kinase Inhibitor Therapy

S. Goldberg, S. Hamarman, 2015 .

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase

S. Goldberg, E. Wu, Lei Chen, 2014, Current medical research and opinion.

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

J. Marshall, N. Rizvi, D. Sterman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.

M. Laouri, E. Chen, A. Pecora, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

J. Cortes, J. Kolitz, J. Lancet, 2017 .

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

R M Stone, R. Larson, H. Dombret, 2008, Leukemia.

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

P. Westervelt, P. Fenaux, H. Fingert, 2010 .

Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.

S. Goldberg, A. Rao, I. Redei, 1996, Bone marrow transplantation.

The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease.

G. Dewald, S. Goldberg, P. Noel, 1998, American journal of clinical oncology.

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

J. Lancet, S. Goldberg, G. Uy, 2022, Blood advances.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

P. Venugopal, H. Kantarjian, T. Kadia, 2012 .

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

P. Hari, D. Madduri, J. Castillo, 2020, American journal of hematology.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

J. Lancet, S. Goldberg, G. Uy, 2020, Transplantation and Cellular Therapy.

Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.

A. Goy, A. Pecora, S. Goldberg, 2009 .

Autologous bone marrow transplantation in primary breast cancer : the American experience

J. Fay, L. Akard, C. Cirrincione, 1995 .

The palatability and tolerability of deferasirox taken with different beverages or foods

E. Vichinsky, S. Goldberg, C. Paley, 2013, Pediatric Blood & Cancer.

One-Year Post-Transplant Serum Ferritin Level Is a Predictor of Long-Term Survival Following Allogeneic Transplantation.

A. Mato, A. Pecora, S. Goldberg, 2010 .

Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.

L. Akard, A. Pecora, S. Goldberg, 2015, Journal of oncology practice.

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

T. Kipps, A. Chanan-Khan, S. Stilgenbauer, 2011 .

Lack of transmission of neutrophil and platelet antibodies by intravenous immunoglobulin in bone marrow transplant patients

J. Herman, S. Goldberg, K. Mangan, 1994, Transfusion.

Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma.

D. Siegel, A. Pecora, S. Goldberg, 2004 .

Outcomes in Older Patients with Newly Diagnosed, High‐risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX‐351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin: AML‐275

J. Cortes, J. Kolitz, J. Lancet, 2018, Clinical Lymphoma Myeloma and Leukemia.

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

M. Tan, R. Feinman, R. Korngold, 2021, JCI insight.

Real-world economic value of a 21-gene assay in early-stage breast cancer.

R. Pe Benito, A. Pecora, D. McNamara, 2017, The American journal of managed care.

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

R. Larson, M. Baccarani, H. Kantarjian, 2012, Leukemia.

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).

R. Larson, R. Clark, H. Kantarjian, 2014 .

A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

G. Ossenkoppele, S. Goldberg, G. Alimena, 2008 .

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

J. Radich, A. Yang, D. DeAngelo, 2009 .

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

R. Larson, H. Kantarjian, G. Rosti, 2010 .

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).

I. Flinn, R. Larson, H. Kantarjian, 2012 .

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

D. Siegel, R. Feinman, D. Vesole, 2019, Blood.

Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia?

S. Goldberg, G. Schechter, T. Mehlman, 1990, The New England journal of medicine.

Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists

J. Snowdon, A. Norden, A. Pecora, 2019, Cancer medicine.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

S. Goldberg, E. Wu, Lei Chen, 2014, Journal of medical economics.

Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiency

C. Kessler, S. Goldberg, C. Orthner, 1991, American journal of hematology.

Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).

J. Cortes, R. Paquette, H. Khoury, 2014 .

Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies

S. Goldberg, Laura M. Chiang, S. Hamarman, 2004, Supportive Care in Cancer.

Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.

R. Larson, N. Russell, G. Martinelli, 2014 .

The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).

A. Goy, A. Mato, A. Pecora, 2010 .

Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data

R. Paquette, C. Gambacorti-Passerini, R. Hehlmann, 2020, European journal of haematology.

Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma.

D. Siegel, D. Vesole, A. Pecora, 2020, Clinical lymphoma, myeloma & leukemia.

COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients

Carson K. Lam, G. Tourassi, J. Rassen, 2021, PloS one.

Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study.

M. Baccarani, H. Kantarjian, B. Druker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bariatric surgery and oral chemotherapy: Where is the dosing guidance?

S. Goldberg, 2023, Cancer.

Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood

P. Price, P. Stiff, A. Pecora, 2000, Bone Marrow Transplantation.

Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients

P. Fadda, L. Cavalli, S. Goldberg, 2023, International journal of molecular sciences.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

M. Baccarani, H. Kantarjian, B. Druker, 2007 .

Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need

M. Laouri, E. Chen, S. Goldberg, 2012, Transfusion.

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

J. Radich, H. Kantarjian, K. McDougall, 2006 .

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

S. Goldberg, S. Faderl, Jamie L. Koprivnikar, 2017 .

Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site.

S. Goldberg, S. Schnall, K. Mangan, 1994, Bone marrow transplantation.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2008 .

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

M. Baccarani, H. Kantarjian, B. Druker, 2007, Blood.

Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD

A. Goy, A. Mato, A. Pecora, 2012, Cancer.

Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL).

D. Siegel, A. Goy, A. Mato, 2010 .

The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.

D. Siegel, D. Vesole, A. Goy, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Patient-Reported Outcome Instrument to Facilitate Timing of End-of-Life Discussions among Patients with Advanced Cancers.

José Miguel Contreras, A. Pecora, S. Goldberg, 2016, Journal of palliative medicine.